Nycomed, Glenmark Settle Feud Over Cutivate

Law360, New York (May 18, 2011, 6:19 PM EDT) -- Drugmaker Nycomed US Inc. reached a settlement in New York on Wednesday in its patent dispute with Glenmark Generics Ltd. that will block Glenmark from producing a generic version of Nycomed's Cutivate skin treatment until March 2012.

The order filed by U.S. District Judge Carol Bagley Amon on Wednesday dismisses all claims and counterclaims filed by the drugmakers during the course of their more than two-year battle. The companies’ feud was sparked by Glenmark's filing of an abbreviated new drug application with the U.S. Food and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.